KYSA-8: A Phase 2 Open-Label, Single-Arm, Multicenter Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
Latest Information Update: 04 Apr 2025
At a glance
- Drugs KYV-101 (Primary)
- Indications Stiff-person syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms KYSA-8
- 27 Mar 2025 According to Kyverna Therapeutics media release, the company anticipates Completion of enrollment is expected in mid-2025.
- 13 Jan 2025 According to Kyverna Therapeutics media release, the company has done 40% enrollment in pivotal Phase 2 trial with first BLA filing targeted for 2026.
- 13 Nov 2024 According to Kyverna Therapeutics media release, for KYSA-8 KYV-101 has been granted an RMAT designation and Orphan Drug Designation by the U.S. Food and Drug Administration (FDA).